Clinical trial

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD)…

NCT00199433 · Kyowa Kirin, Inc., Industry · Completed

Key facts

NCT number NCT00199433
Title A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Official title A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease
Lead sponsor Kyowa Kirin, Inc., Industry
Collaborators Kyowa Kirin Co., Ltd. Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Parkinson's Disease, Movement Disorder Syndrome
Intervention type Drug
Interventions Istradefylline (KW-6002)
Enrollment 160
Start date May 1, 2005
Primary completion Jul 1, 2006
Completion Aug 1, 2006
First posted Sep 20, 2005
Last update posted Apr 25, 2024
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies